Get the latest news, insights, and market updates on MREO (Mereo BioPharma Group plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Mereo BioPharma Group (MREO) Is Up 74.4% After Mixed Setrusumab Phase 3 Data and Cash Update – Has The Bull Case Changed?
Mereo BioPharma recently reported mixed Phase 3 results for setrusumab in osteogenesis imperfecta, updated its cash runway to around US$41,000,000 through mid-2027, and outlined next steps for alvelestat and out-licensed vantictumab. While setrusumab missed its primary fracture endpoints, the strong, statistically significant gains in bone mineral density highlight a complex risk‑reward profile for this rare disease asset. We’ll now examine how the strong bone mineral density data, despite... Jan 16, 2026 - $MREO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.